Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Rigel Pharmaceuticals Inc as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- −11 vs. Q2 2023
- Shares held
- 106.3M
- −4.37M (−3.9%) vs. Q2 2023
- Total value
- $114.8M
- −$28.0M (−19.6%) vs. Q2 2023
- New holders
- 6
- 34 more added
- Sold out
- 17
- 34 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RIGL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 155 | $640.4M |
| Q1 2026 | 159 | $432.8M |
| Q4 2025 | 194 | $690.5M |
| Q3 2025 | 169 | $425.6M |
| Q2 2025 | 126 | $260.2M |
| Q1 2025 | 123 | $250.2M |
| Q4 2024 | 122 | $203.0M |
| Q3 2024 | 93 | $192.6M |
| Q2 2024 | 91 | $85.4M |
| Q1 2024 | 117 | $164.3M |
| Q4 2023 | 113 | $154.5M |
| Q3 2023 | 106 | $114.8M |
| Q2 2023 | 118 | $142.7M |
| Q1 2023 | 125 | $148.6M |
| Q4 2022 | 118 | $163.1M |
| Q3 2022 | 138 | $150.3M |
| Q2 2022 | 135 | $157.2M |
| Q1 2022 | 163 | $405.7M |
| Q4 2021 | 162 | $365.9M |
| Q3 2021 | 163 | $499.6M |
| Q2 2021 | 160 | $614.5M |
| Q1 2021 | 152 | $493.1M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Rigel Pharmaceuticals Inc; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 4,660,740 | $5.03M | 0.02% | +79,228+1.7% | Added |
| Morgan Stanley | 6,982,475 | $7.54M | 0.00% | +3,118,154+80.7% | Added |
| Vanguard Group Inc | 8,867,750 | $9.58M | 0.00% | −2,069,079−18.9% | Reduced |
| BlackRock Inc. | 14,413,495 | $15.6M | 0.00% | −204,097−1.4% | Reduced |
| Soleus Capital Management, L.P. | 14,803,015 | $16.0M | 1.61% | +625,000+4.4% | Added |
| Armistice Capital, LLC | 17,136,000 | $18.5M | 0.55% | +36,000+0.2% | Added |
| Tamarack Advisers, LP | 0 | $0 | 0.00% | −1,250,000−100.0% | Sold out |
| Putnam Investments LLC | 0 | $0 | 0.00% | −255,730−100.0% | Sold out |
| Rhenman & Partners Asset Management AB | 0 | $0 | 0.00% | −253,832−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −101,240−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −89,235−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −50,288−100.0% | Sold out |
| Visionary Wealth Advisors | 0 | $0 | 0.00% | −22,297−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,929−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −14,854−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −12,868−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −10,073−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −11,026−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Worth Asset Management, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Column Capital Advisors, LLC | 0 | $0 | 0.00% | −310−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −87−100.0% | Sold out |
| BerganKDV Wealth Management, LLC | – | – | – | – | Not filed |